[go: up one dir, main page]

DK2197860T3 - Nye forbindelser som adenosin-A1-receptorantagonister - Google Patents

Nye forbindelser som adenosin-A1-receptorantagonister

Info

Publication number
DK2197860T3
DK2197860T3 DK08835072.3T DK08835072T DK2197860T3 DK 2197860 T3 DK2197860 T3 DK 2197860T3 DK 08835072 T DK08835072 T DK 08835072T DK 2197860 T3 DK2197860 T3 DK 2197860T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
straight
branched
group
halogen atoms
Prior art date
Application number
DK08835072.3T
Other languages
English (en)
Inventor
Lio Lyhen Gonzalez
Gomez Juan Alberto Camacho
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Application granted granted Critical
Publication of DK2197860T3 publication Critical patent/DK2197860T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DK08835072.3T 2007-10-02 2008-09-30 Nye forbindelser som adenosin-A1-receptorantagonister DK2197860T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702643A ES2331220B1 (es) 2007-10-02 2007-10-02 Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
PCT/IB2008/002556 WO2009044250A1 (en) 2007-10-02 2008-09-30 New compounds as adenosine a1 receptor antagonists

Publications (1)

Publication Number Publication Date
DK2197860T3 true DK2197860T3 (da) 2011-08-15

Family

ID=40303525

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08835072.3T DK2197860T3 (da) 2007-10-02 2008-09-30 Nye forbindelser som adenosin-A1-receptorantagonister

Country Status (20)

Country Link
US (1) US8410282B2 (da)
EP (1) EP2197860B1 (da)
JP (1) JP5463592B2 (da)
KR (1) KR101312198B1 (da)
CN (1) CN101835766B (da)
AT (1) ATE510829T1 (da)
AU (1) AU2008306553B2 (da)
BR (1) BRPI0816554B8 (da)
CA (1) CA2700526C (da)
CY (1) CY1112079T1 (da)
DK (1) DK2197860T3 (da)
EA (1) EA022473B1 (da)
ES (2) ES2331220B1 (da)
HR (1) HRP20110557T1 (da)
MX (1) MX2010003576A (da)
PL (1) PL2197860T3 (da)
PT (1) PT2197860E (da)
SI (1) SI2197860T1 (da)
WO (1) WO2009044250A1 (da)
ZA (1) ZA201002139B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP2941420B1 (en) * 2013-01-03 2018-09-05 Council of Scientific & Industrial Research (4e)-4-(4-substituted benzylideneamino)-2,3-dihydro-3- substituted-2-thioxothiazole-5-carbonitriles as a2ar antagonist and process for preparation thereof
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
HRP20211104T1 (hr) 2017-03-06 2021-10-15 Palobiofarma, S.L. Aminska sol (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksilne kiseline
CN107739350B (zh) * 2017-09-26 2020-12-22 天津大学 一种合成2-氨基噻唑衍生物的方法
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
EP3882240A1 (en) 2020-03-16 2021-09-22 Palobiofarma, S.L. Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CN119039300A (zh) * 2024-08-29 2024-11-29 上海信诺维生物医药有限公司 吡唑并嘧啶类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039451A2 (en) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
CN1319967C (zh) * 2002-01-18 2007-06-06 安斯泰来制药有限公司 2-酰基氨基噻唑衍生物或其盐
EP2460800A1 (en) * 2006-03-08 2012-06-06 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina

Also Published As

Publication number Publication date
AU2008306553B2 (en) 2011-06-09
CA2700526C (en) 2014-03-18
JP5463592B2 (ja) 2014-04-09
EP2197860A1 (en) 2010-06-23
ES2331220B1 (es) 2010-09-23
BRPI0816554B1 (pt) 2019-04-09
SI2197860T1 (sl) 2011-09-30
EA022473B1 (ru) 2016-01-29
CN101835766A (zh) 2010-09-15
MX2010003576A (es) 2010-04-22
ATE510829T1 (de) 2011-06-15
CY1112079T1 (el) 2015-11-04
JP2010540615A (ja) 2010-12-24
EP2197860B1 (en) 2011-05-25
EA201000393A1 (ru) 2010-08-30
BRPI0816554B8 (pt) 2022-08-30
KR20100058653A (ko) 2010-06-03
ES2366075T3 (es) 2011-10-17
PL2197860T3 (pl) 2011-09-30
US8410282B2 (en) 2013-04-02
BRPI0816554A2 (pt) 2015-11-24
ES2331220A1 (es) 2009-12-23
WO2009044250A1 (en) 2009-04-09
PT2197860E (pt) 2011-08-26
CA2700526A1 (en) 2009-04-09
AU2008306553A1 (en) 2009-04-09
KR101312198B1 (ko) 2013-09-27
HRP20110557T1 (hr) 2011-09-30
US20100311703A1 (en) 2010-12-09
ZA201002139B (en) 2011-06-29
CN101835766B (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
DK2197860T3 (da) Nye forbindelser som adenosin-A1-receptorantagonister
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
EA201170096A1 (ru) Замещенные производные пиримидона
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
BRPI0910871A2 (pt) derivados espirocíclicos como inibidores de histona desacetilase
SMT201300085B (it) Composti di pirrolo
CO6420337A2 (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
UY32481A (es) Derivados de benzofurano
MY152281A (en) 4-pyrimidinesulfamide derivative
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
MA32296B1 (fr) Derives de piperidine 3,4-substitues comme inhibiteurs de la renine
BR112014032229A2 (pt) método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
EA201170606A1 (ru) Феназопиридиновые соединения
WO2009130469A8 (en) Dna-pk inhibitors
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
NI201200039A (es) Nuevos derivados dihidro - oxazolobenzodiazepinonas, su procedi
EA200802427A1 (ru) Новые соединения 1н-индол-1-ил-мочевины, способ их получения и фармацевтические композиции, содержащие их
AR077084A1 (es) Esteres derivados de azetidinas, su preparacion y su aplicacion en terapeutica